Shares slide; Xero drops; energy regulator in rare U-turn over APA’s Basslink power cable; Cue Clothing CEO joins Myer.

Macquarie described Neuren Pharmaceuticals shares as a standout in the biotech industry and set a price target of $18.60 on ...

Broker UBS believes the three-year rout of ASX healthcare stocks is near an end and it has promoted Cochlear and Resmed to ...

Morgans senior analyst Scott Power said markets are holding their ground with ASX 200 Health Care index up 1.2% for week ending May 30, 2025.

View the latest Neuren Pharmaceuticals Ltd. (NEU) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Neuren Pharmaceuticals Neuren Pharmaceuticals is a biotech developing drugs for rare neurological disorders. Its lead treatment, Daybue, is approved for Rett syndrome, while its second candidate, ...

Shares of Neuren Pharmaceuticals Ltd (ASX:NEU) jumped over 10% on Thursday after the company announced a key development in ...